EN DE
Watch SenzaGen AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SenzaGen AB (SENZA) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of SenzaGen AB stock SEK 4.36, price SEK 4.75, that is 8.2% below the price, quality 36 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0010219626

SA SenzaGen AB logo Thin data Nov 10, 2026

SenzaGen AB

SENZA · ST
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value kr 4.36 · Fairly valued
Expensive Growth (revenue 5y +48.8 %/yr in SEK)
Mixed vs. peers (5/10)
Quality 36/100
Loss-making · -15.2% net margin (TTM)
Negative free cash flow
Narrow moat 16/100
Thin data
Estimate
Watch SenzaGen AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 20.90 kr 4.18 Fair Value kr 4.36 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 4.18 – kr 20.90 · fair‑value band kr 3.27 – kr 5.45 · the kr 4.75 price screens above the kr 4.36 fair value. As of Nov 10, 2026.

Follow SenzaGen in your weekly email

Every Wednesday you see whether SenzaGen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment.

Show moreShow less

It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices.

In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, skin sensitization, and skin absorption; and eye irritation, phototoxicity, and cytotoxicity testing services and advisory services to pharma, medial devices, cosmetics, an chemical industries.

Further, it provides SenzaGen, a test portfolio to assess toxicity of chemicals, cosmetics, medical devices, drug candidates, and nutrition/food additives. The company offers services through license partners and distributors.

It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden.

Stock analysis

SenzaGen AB (SENZA) currently trades at kr 4.75, while our estimate is kr 4.36, so the stock looks roughly fairly valued today (gap 8.9%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 3.27 (bear) to kr 5.45 (bull), the price of kr 4.75 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

SenzaGen AB reported revenue of 58.0M SEK in FY2025 versus 15.4M SEK in FY2021, a compound +39.2%/yr. Reported net income was −11.6M SEK in FY2025.

Key figures

Market cap 154M SEK (≈ $15.7M) Micro · P/S ratio 2.55 · EPS (TTM) kr −0.3500 · Net margin −15.2% · Return on equity −11.1% · Return on assets (EBIT) −16.5% (5-year average) · Operating margin −13.8% · Revenue (TTM) 61.0M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 28% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −8%, SENZA screens cheaper than that median.

Fair Value

Bear kr 3.27 Fair Value kr 4.36 Bull kr 5.45
Price kr 4.75 · Downside -8.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 18
How much profit the company makes from its sales and capital
Quality Growth 54
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 68
Debt, balance sheet and risk of trouble
Investment 94
Does it invest with discipline instead of growing at any price?
Low Volatility 71
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.8%
Start year 2020 (pandemic). Over 10 years: +41.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−340.5% (2020) → −19.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch SENZA, get fair value alerts →

Compare SenzaGen AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 149 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −8.2% · Above median
Profitability
Return on assets −10.0% · Below median
Net margin (12 months) −15.2% · Bottom 25%
Operating margin (12 months) −13.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 13.2% · Above median
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 1.99× · Cheaper than median
P/S (12 months) 2.53× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 12
FUTURE (revenue growth)66 · sector 40
PAST (return on equity)0 · sector 7
HEALTH (low debt)97 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥150.30 ¥165.32 +10% vs SENZA
Illumina, Inc ILMN $214.91 $234.44 +9% vs SENZA
IQVIA Holdings IQV $275.15 $299.58 +9% vs SENZA
Thermo Fisher Scientific Inc TMO $718.20 $686.04 −4% vs SENZA
Danaher Corporation DHR $236.11 $209.18 −11% vs SENZA
IDEXX Laboratories, Inc IDXX $696.64 $496.48 −29% vs SENZA
Mettler-Toledo International Inc MTD $1,751 $655.06 −63% vs SENZA
Agilent Technologies, Inc A $177.88 $64.53 −64% vs SENZA
Lonza Group LONN CHF 661.00 CHF 153.50 −77% vs SENZA
Waters Corporation WAT $475.52 $91.26 −81% vs SENZA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SenzaGen AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SenzaGen AB Fair Value". https://www.fairvalue-calculator.com/stock/SENZA

Frequently asked questions

Is SenzaGen AB (SENZA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 4.36 versus a price of kr 4.75, about 8% lower (fairly valued).
What is the fair value of SENZA?
Our estimate for SenzaGen AB is kr 4.36 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 4.75.
What is the quality score of SENZA?
SenzaGen AB has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SenzaGen AB (SENZA)?
Our calculated price target is the estimate of kr 4.36 (as of Nov 10, 2026). Cautious scenario kr 3.27, optimistic scenario kr 5.45. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the SenzaGen AB stock forecast for 2026?
Our estimate puts fair value at kr 4.36, about 8% lower versus a price of kr 4.75 (fairly valued). Cautious scenario kr 3.27, optimistic scenario kr 5.45. The calculation is refreshed regularly with new filings.
What is the revenue of SenzaGen AB (SENZA)?
SenzaGen AB reported trailing-twelve-month revenue of about 61.0M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of SenzaGen AB (SENZA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SenzaGen AB it is kr 4.36 per share (as of Nov 10, 2026), against a price of kr 4.75.
Is SenzaGen AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SENZA trades above its calculated fair value: price kr 4.75, fair value kr 4.36, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SENZA?
No. The price is what the market pays today (kr 4.75); the fair value is what the company's own numbers justify (kr 4.36). For SenzaGen AB the two are kr 0.3900 per share apart. That gap is exactly why we show both numbers side by side.
How much is SenzaGen AB worth?
The market values SenzaGen AB at about 154M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 4.75; our models calculate a fair value of kr 4.36 per share.
What do the bullish and bearish scenarios say about SENZA?
Our models span a range for SenzaGen AB: cautious scenario kr 3.27, base kr 4.36, optimistic kr 5.45 per share (as of Nov 10, 2026, price kr 4.75). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SenzaGen AB (SENZA)?
Balance-sheet figures for SenzaGen AB (as of Nov 10, 2026): return on equity −11.1%, debt of 0.07 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is SENZA from its 52-week high?
SenzaGen AB trades at kr 4.75, about 28% below its 52-week high of kr 6.60 and 9% above the low of kr 4.35 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 4.36 is for.
Which stocks are comparable to SenzaGen AB?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SenzaGen AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 4.75, calculated fair value kr 4.36 (−8%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. SenzaGen AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SenzaGen AB (SENZA)?
The closing price on Nov 10, 2026 was kr 4.75. Our estimate is kr 4.36, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SenzaGen AB right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of SenzaGen AB

How large is the market capitalisation of SenzaGen AB (SENZA)?
The market capitalisation of SenzaGen AB is 154M SEK (≈ $15.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SenzaGen AB (SENZA)?
The price-to-sales ratio of SenzaGen AB is 2.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SenzaGen AB (SENZA)?
Earnings per share at SenzaGen AB are kr −0.3500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SenzaGen AB (SENZA)?
The net margin of SenzaGen AB is −15.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SenzaGen AB (SENZA)?
The return on equity (ROE) of SenzaGen AB is −11.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SenzaGen AB (SENZA)?
On an EBIT basis the return on assets of SenzaGen AB is −16.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SenzaGen AB (SENZA)?
The operating margin of SenzaGen AB is −13.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SenzaGen AB (SENZA)?
Revenue at SenzaGen AB is growing +13.2% versus a year earlier (3y avg +11.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SenzaGen AB (SENZA) generate?
The free cash flow of SenzaGen AB is −10.1M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SenzaGen AB (SENZA) carry?
The net debt of SenzaGen AB is 1.9M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch SenzaGen AB in the live analysis

One click puts SenzaGen AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.